vs

Side-by-side financial comparison of Ascendis Pharma A/S (ASND) and IMMERSION CORP (IMMR). Click either name above to swap in a different company.

IMMERSION CORP is the larger business by last-quarter revenue ($372.9M vs $267.3M, roughly 1.4× Ascendis Pharma A/S). On growth, IMMERSION CORP posted the faster year-over-year revenue change (750.4% vs 42.3%). Over the past eight quarters, IMMERSION CORP's revenue compounded faster (537.9% CAGR vs 60.7%).

Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.

Immersion Corporation is an Aventura, Florida based developer and licensor of touch feedback technology, also known as haptic technology. Immersion Corporation has been accused of being a patent troll. Founded in 1993 by Louis Rosenberg, it is currently headed by lawyer Francis Jose, who serves as both chief executive officer and general counsel.

ASND vs IMMR — Head-to-Head

Bigger by revenue
IMMR
IMMR
1.4× larger
IMMR
$372.9M
$267.3M
ASND
Growing faster (revenue YoY)
IMMR
IMMR
+708.1% gap
IMMR
750.4%
42.3%
ASND
Faster 2-yr revenue CAGR
IMMR
IMMR
Annualised
IMMR
537.9%
60.7%
ASND

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASND
ASND
IMMR
IMMR
Revenue
$267.3M
$372.9M
Net Profit
$-17.0M
Gross Margin
90.5%
Operating Margin
-2.8%
Net Margin
-4.6%
Revenue YoY
42.3%
750.4%
Net Profit YoY
-191.3%
EPS (diluted)
$-0.57

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASND
ASND
IMMR
IMMR
Q4 25
$267.3M
Q3 25
$230.7M
Q2 25
$170.7M
$372.9M
Q1 25
$109.0M
$471.3M
Q4 24
$187.8M
$616.2M
Q3 24
$62.5M
Q2 24
$38.9M
$95.5M
Q1 24
$103.6M
$43.8M
Net Profit
ASND
ASND
IMMR
IMMR
Q4 25
Q3 25
$-65.9M
Q2 25
$-42.0M
$-17.0M
Q1 25
$-102.2M
$24.1M
Q4 24
$30.8M
Q3 24
$-107.1M
Q2 24
$-118.1M
$26.4M
Q1 24
$-141.5M
$18.7M
Gross Margin
ASND
ASND
IMMR
IMMR
Q4 25
90.5%
Q3 25
89.5%
Q2 25
80.1%
Q1 25
82.6%
Q4 24
91.9%
Q3 24
80.6%
Q2 24
68.2%
Q1 24
92.1%
Operating Margin
ASND
ASND
IMMR
IMMR
Q4 25
Q3 25
5.1%
Q2 25
-33.5%
-2.8%
Q1 25
-103.2%
7.5%
Q4 24
11.4%
Q3 24
-167.3%
Q2 24
-370.2%
23.7%
Q1 24
-51.2%
37.9%
Net Margin
ASND
ASND
IMMR
IMMR
Q4 25
Q3 25
-28.5%
Q2 25
-24.6%
-4.6%
Q1 25
-93.7%
5.1%
Q4 24
5.0%
Q3 24
-171.5%
Q2 24
-303.9%
27.7%
Q1 24
-136.6%
42.5%
EPS (diluted)
ASND
ASND
IMMR
IMMR
Q4 25
Q3 25
Q2 25
$-0.57
Q1 25
$0.73
Q4 24
$0.93
Q3 24
Q2 24
$0.81
Q1 24
$0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASND
ASND
IMMR
IMMR
Cash + ST InvestmentsLiquidity on hand
$665.3M
$161.4M
Total DebtLower is stronger
$103.1M
Stockholders' EquityBook value
$-175.8M
$298.1M
Total Assets
$1.4B
$1.1B
Debt / EquityLower = less leverage
0.35×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASND
ASND
IMMR
IMMR
Q4 25
$665.3M
Q3 25
$582.2M
Q2 25
$533.6M
$161.4M
Q1 25
$559.4M
$153.9M
Q4 24
$604.3M
$159.3M
Q3 24
$675.6M
Q2 24
$279.4M
$133.4M
Q1 24
$345.9M
$179.1M
Total Debt
ASND
ASND
IMMR
IMMR
Q4 25
Q3 25
Q2 25
$103.1M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ASND
ASND
IMMR
IMMR
Q4 25
$-175.8M
Q3 25
$-188.0M
Q2 25
$-202.6M
$298.1M
Q1 25
$-205.0M
$317.9M
Q4 24
$-114.2M
$305.5M
Q3 24
$-105.1M
Q2 24
$-346.8M
$273.4M
Q1 24
$-257.2M
$201.5M
Total Assets
ASND
ASND
IMMR
IMMR
Q4 25
$1.4B
Q3 25
$1.2B
Q2 25
$1.2B
$1.1B
Q1 25
$1.1B
$1.4B
Q4 24
$1.3B
$1.4B
Q3 24
$1.2B
Q2 24
$819.0M
$1.2B
Q1 24
$866.7M
$244.7M
Debt / Equity
ASND
ASND
IMMR
IMMR
Q4 25
Q3 25
Q2 25
0.35×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASND
ASND
IMMR
IMMR
Operating Cash FlowLast quarter
$58.2M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASND
ASND
IMMR
IMMR
Q4 25
$58.2M
Q3 25
Q2 25
Q1 25
$-15.5M
$-43.7M
Q4 24
$-330.7M
Q3 24
Q2 24
$-85.9M
Q1 24
$-109.7M
$29.9M
Free Cash Flow
ASND
ASND
IMMR
IMMR
Q4 25
Q3 25
Q2 25
Q1 25
$-46.2M
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
ASND
ASND
IMMR
IMMR
Q4 25
Q3 25
Q2 25
Q1 25
-9.8%
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
ASND
ASND
IMMR
IMMR
Q4 25
Q3 25
Q2 25
Q1 25
0.5%
Q4 24
Q3 24
Q2 24
Q1 24
Cash Conversion
ASND
ASND
IMMR
IMMR
Q4 25
Q3 25
Q2 25
Q1 25
-1.82×
Q4 24
Q3 24
Q2 24
-3.25×
Q1 24
1.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASND
ASND

Segment breakdown not available.

IMMR
IMMR

Course Material Sale$150.9M40%
General Merchandise Sale$138.0M37%
Rental Services$51.8M14%
Services And Other Revenue$25.6M7%
Per Unit Royalties$1.8M0%

Related Comparisons